Alzheimer’s disease: Treatments in discovery and development

Nature Neuroscience

Volumn 5, Issue 11s, 2002, Pages 1055-1057

  Citron, Martin ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID; AMYLOID BETA ANTIBODY; AMYLOID BETA PROTEIN; ATORVASTATIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CLIOQUINOL; ENZYME INHIBITOR; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; VACCINE; ZINC;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION; DRUG INDUSTRY; ENZYME INHIBITORS; HUMANS;

EID: 0036828769     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn940     Document Type: Review

References (29)

1. Davis, K. L. & Samuels, S. C. in Pharmacological Management of Neurological and Psychiatric Disorders (eds. Enna, S. J. & Coyle, J. T.) 267-316 (McGraw-Hill, New York, 1998).
2. Doody, R. S. Therapeutic standards in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 13, S20-S26 (1999).
3. Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. 12, 383-388 (1991).
4. Joachim, C. L. & Selkoe, D. J. The seminal role of ß-amyloid in the pathogenesis of Alzheimer Disease. Alzheimer Dis. Assoc. Disord. 6, 7-34 (1992).
5. Younkin, S. G. The role of A beta 42 in Alzheimer’s disease. J. Physiol. (Paris) 92, 289-292 (1998).
6. Selkoe, D. J. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 399, A23-A31 (1999).
7. Leung, D., Abbenante, G. & Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 43, 305-341 (2000).
8. Francis, R. et al. Aph-1 and pen-2 are required for Notch pathway signaling, y-secretase cleavage of APP, and presenilin protein accumulation. Dev. Cell 3, 85-97 (2002).
9. Sisodia, S. S. & St George-Hyslop, P. H. y-secretase, Notch, Aß and Alzheimer’s disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3, 281-290 (2002).
10. Vassar, R. et al. ß-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741 (1999).
11. Hong, L. et al. Structure of the protease domain of memapsin 2 (ß-secretase) complexed with inhibitor. Science 290, 150-153 (2000).
12. Luo, Y. et al. Mice deficient in BACE1, the Alzheimer’s ß-secretase, have normal phenotype and abolished ß-amyloid generation. Nat. Neurosci. 4, 231-232 (2001).
13. Citron M. ß-secretase as a target for the treatment of Alzheimer’s disease. J. Neurosci. Res. (in press).
14. Sinha, S. et al. Purification and cloning of amyloid precursor protein ß-secretase from human brain. Nature 402, 537-540 (1999).
15. Hock, B. J. & Lamb, B. T. Transgenic mouse models of Alzheimer’s disease. Trends Genet. 17, S7-S12 (2001).
16. Soto, C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer’s disease. Mol. Med. Today 5, 343-350 (1999).
17. Cherny, R. A. et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits ß-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30, 665-676 (2001).
18. Bush, A. & Tanzi, R. E. The galvanization of ß-amyloid in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 99, 7317-7319 (2002).
19. Schenk, D. et al. Immunization with amyloid-ß attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
20. Bard, F. et al. Peripherally administered antibodies against amyloid ß-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919 (2000).
21. De Mattos, R. B. et al. Peripheral anti-Aß antibody alters CNS and plasma A ß clearance and decreases brain Aß burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 98, 8850-8855 (2001).
22. Steinberg, D. Companies halt first Alzheimer vaccine trial. The Scientist 16, 22-23 (2002).
23. McGeer, P. L. & McGeer, E. G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22, 799-809 (2001).
24. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Aß42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
25. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G. & Siegel, G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443 (2000).
26. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. & Drachman, D. A. Statins and the risk of dementia. Lancet 356, 1627-1631 (2000).
27. Fassbender, K. et al. Simvastatin strongly reduces levels of Alzheimer’s disease ß-amyloid peptides Aß42 and Aß40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 5856-5861 (2001).
28. Golde, T. E. & Eckman, C. B. Cholesterol modification as an emerging strategy for the treatment of Alzheimer’s disease. Drug Discov. Today 6, 1049-1055 (2001).
29. Puglielli, L. et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid ß-peptide. Nat. Cell Biol. 3, 905-912 (2001).